MENS:NASDAQ, Jyong Biotech Ltd.

MENS stock overview

Jyong Biotech Ltd. (MENS:NASDAQ) closed at $1.80 on November 17, 2026, up 1.69% on the day. The stock trades 95.4% below its 52-week high of $38.88 and 25.9% above its 52-week low of $1.43. Over the past year, it lost 94.1%. Jyong Biotech Ltd. is part of the Health Care sector.

Key figures

Price
$1.80
Day change
+1.69%
Volume
14,104
Average volume
42,125
Market cap
136M+
52-week range
$1.43 – $38.88
50-day average
$1.96
200-day average
$2.09

Price action over the past year

In 252 trading sessions since November 14, 2025, MENS closed higher on 107 days (42%). Its best day was December 30, 2025 (+51.80%) and its worst was December 17, 2025 (-81.04%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

MENS news

About Jyong Biotech Ltd.

Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan. Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.

Similar stocks

Find more stocks like MENS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.